Quercetin, luteolin, linolenic acid, adenosine, kaempferol, etc., were considered the potential core compounds, and PTGS2, ESR1, PTGS1, NOS2, AKT1, etc. were the main potential targets of BSYQ for asthma and IPF therapy. The gene discussed is PTGS2; the disease is asthma.